MANCHESTER, UK - Donald Stull, PhD, a health outcomes researcher with over 25 years of experience, recently joined RTI Health Solutions (RTI-HS) as a Director of Retrospective Data Analysis. He will be based in our Manchester, UK office.
Donald brings considerable expertise in health outcomes and health services research, including studies of the measurement of physical and mental health; the validity of patient-reported health; and studies of health outcomes, such as mortality, hospitalization and physician visits. Dr. Stull has particular expertise in psychometrics and his current work involved the use of latent growth model (LGM) and growth modeling techniques in designing and analyzing data from clinical trials, observational studies, registries, electronic medical records, and claims data.
Most recently he comes to us after spending the last 6 years at UBC in the US, having previously been based at Medstat in Washington, and the University of Maryland School of Nursing.
"Donald has an impressive combination of patient-reported, economic, and clinical outcomes experience that will greatly enhance our service offerings to clients in Europe. We are very excited that he has joined our team!" said Steve Beard, MSc, Vice President of Health Economics, Europe.
Donald has his PhD in Sociology, earned from the University of Washington, in Seattle Washington.
Dr. Stull's work has led to articles in publications such as Journals of Gerontology: Psychology Sciences, Journals of Gerontology: Social Sciences, Heart and Lung, Research in Nursing and Health, Journal of Applied Gerontology, Value in Health, Quality of Life Research, Current Medical Research and Opinion, and Contemporary Clinical Trials. In addition, he was a coeditor of an award-winning book, Ethnic Elderly and Long-Term Care (Springer). He is Editor-in-Chief of Health Outcomes Research in Medicine, published by Elsevier.
About RTI Health Solutions
RTI Health Solutions provides scientifically rigorous research and consulting services in health economics, patient-reported outcomes, market access and outcomes strategy, health preference assessment, epidemiology, biometrics, drug safety and pharmacovigilance, to help biopharmaceutical companies successfully develop and gain market approval for their products.